As of 2024-10-12, the Relative Valuation of Supernus Pharmaceuticals Inc (SUPN) is 1.53 USD. This relative valuation is based on P/E multiples. With the latest stock price at 33.00 USD, the upside of Supernus Pharmaceuticals Inc based on Relative Valuation is -95.4%.
The range of the Relative Valuation is 0.99 - 2.09 USD.
| Range | Selected | |
| Trailing P/E multiples | 10.5x - 20.3x | 12.8x |
| Forward P/E multiples | 15.4x - 20.3x | 17.8x |
| Fair Price | 0.99 - 2.09 | 1.53 |
| Upside | -97.0% - -93.7% | -95.4% |
| Date | P/E |
| 2024-10-11 | 348.73 |
| 2024-10-10 | 337.00 |
| 2024-10-09 | 342.18 |
| 2024-10-08 | 343.45 |
| 2024-10-07 | 338.80 |
| 2024-10-04 | 338.37 |
| 2024-10-03 | 339.22 |
| 2024-10-02 | 339.85 |
| 2024-10-01 | 338.16 |
| 2024-09-30 | 329.50 |
| 2024-09-27 | 324.95 |
| 2024-09-26 | 325.16 |
| 2024-09-25 | 316.39 |
| 2024-09-24 | 323.05 |
| 2024-09-23 | 332.03 |
| 2024-09-20 | 336.26 |
| 2024-09-19 | 339.54 |
| 2024-09-18 | 336.47 |
| 2024-09-17 | 335.20 |
| 2024-09-16 | 332.67 |
| 2024-09-13 | 328.76 |
| 2024-09-12 | 326.54 |
| 2024-09-11 | 328.44 |
| 2024-09-10 | 353.91 |
| 2024-09-09 | 358.35 |
| 2024-09-06 | 357.61 |
| 2024-09-05 | 363.31 |
| 2024-09-04 | 369.87 |
| 2024-09-03 | 366.80 |
| 2024-08-30 | 371.56 |
| 2024-08-29 | 369.87 |
| 2024-08-28 | 366.06 |
| 2024-08-27 | 368.81 |
| 2024-08-26 | 368.49 |
| 2024-08-23 | 369.55 |
| 2024-08-22 | 363.95 |
| 2024-08-21 | 366.59 |
| 2024-08-20 | 363.84 |
| 2024-08-19 | 361.52 |
| 2024-08-16 | 365.11 |
| 2024-08-15 | 361.94 |
| 2024-08-14 | 351.58 |
| 2024-08-13 | 355.60 |
| 2024-08-12 | 342.28 |
| 2024-08-09 | 339.22 |
| 2024-08-08 | 332.67 |
| 2024-08-07 | 337.32 |
| 2024-08-06 | 294.62 |
| 2024-08-05 | 295.05 |
| 2024-08-02 | 304.14 |